Journal article

Obesity paradox in people newly diagnosed with type 2 diabetes with and without prior cardiovascular disease

G Thomas, K Khunti, V Curcin, M Molokhia, C Millett, A Majeed, S Paul

Diabetes Obesity and Metabolism | WILEY | Published : 2014

Abstract

AIM: To address the debate on 'obesity paradox' in patients with type 2 diabetes mellitus (T2DM) by evaluating the cardiovascular and mortality risks associated with normal and overweight patients compared to obese at diagnosis of diabetes, separately for patients with and without cardiovascular disease (CVD) before diagnosis. METHODS: A retrospective study with two study cohorts with/without prior CVD (n = 10237/37272) with complete measures of body mass index (BMI) at diagnosis of T2DM from UK General Practice Research Database. Primary outcomes were long-term risks of cardiovascular events (CVEs) and all-cause mortality in patients with normal weight, overweight and obesity at diagnosis. ..

View full abstract

University of Melbourne Researchers

Grants

Funding Acknowledgements

This study is based in part on data from the Full Feature General Practice Research Database obtained under licence from the UK Medicines and Healthcare Products Regulatory Agency. Access to the GPRD database was funded through the Medical Research Council's licence agreement with MHRA. This research was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre at Guy's and St Thomas' National Health Service ( NHS) Foundation Trust and King's College London. The Department of Primary Care & Public Health at Imperial College is grateful for support from the NIHR Collaboration for Leadership in Applied Health Research & Care (CLAHRC) Scheme, the NIHR Biomedical Research Centre scheme, and the Imperial Centre for Patient Safety and Service Quality. The Department of Health Sciences at Leicester University are grateful for support from the NIHR CLAHRC and BRUScheme. G. T. is a fully funded research higher degree student of the University of Queensland. The infrastructure support to S. P.'s group is provided by Therapeutic Innovation Australia. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health, UK.